Benin
Tuberculosis profile
| High HIV burden |
Population  2012 10 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.94 (0.42–1.7) 9.4 (4.2–17)
Mortality (HIV+TB only) 0.3 (0.25–0.37) 3 (2.5–3.7)
Prevalence  (includes HIV+TB) 11 (5.6–18) 110 (55–184)
Incidence  (includes HIV+TB) 7 (5.8–8.3) 70 (58–83)
Incidence (HIV+TB only) 1 (0.84–1.2) 10 (8.3–12)
Case detection, all forms (%) 57 (48–68)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 3 171 (84) Relapse 174 (61)
Smear-negative 305 (8) Treatment after failure 86 (30)
Smear-unknown / not done 0 (0) Treatment after default 23 (8)
Extrapulmonary 316 (8) Other 0 (0)
Other 0 (0)      
Total new 3 792   Total retreatment 283  
           
Other (history unknown) 0        
Total new and relapse 3 966   Total cases notified 4 075  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 1.9    
Age < 15 62    
Laboratories 2012
Smear (per 100 000 population) 0.8
Culture (per 5 million population) 0.5
Drug susceptibility testing (per 5 million population) 0.5
Is second-line drug susceptibility testing available? Yes, in and outside
country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 90   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 86  
Retreatment 84  
TB/HIV 2012 Number (%)
TB patients with known HIV status 4 006 (98)
HIV-positive TB patients 637 (16)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART)    
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 0.5 (0.06–2) 13 (8.2–20)
MDR-TB cases among notified pulmonary
TB cases
17 (2–70) 37 (23–55)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 26 (<1%) 110 (39%) 136
Laboratory-confirmed MDR-TB cases 1 7 25
Patients started on MDR-TB treatment     8
Financing TB control 2013
National TB programme budget (US$ millions) 2.3
% Funded domestically 26%
% Funded internationally 74%
% Unfunded 0%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-20 Data: www.who.int/tb/data